Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
Status:
Completed
Trial end date:
2019-03-19
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to demonstrate the clinical efficacy at week 16; and to
demonstrate safety and tolerability of secukinumab compared to placebo in patients with
ankylosing spondylitis at week 16 and long term safety up to Week 52.